Revenio Group Corporation’ has published Annual Report, Report by the Board of Directors and Financial Statements, Corporate Governance Statement, Remuneration Report of 2020
Revenio Group Corporation has published Annual Report, Report by the Board of Directors and Financial Statements of 2020 in company’s internet pages, in Finnish and English at:
The Annual Report contains an annual review, which provides information on Revenio's business and operating environment. Report by the Board of Directors and Financial Statements of 2020 contains Report by the Board of Directors and Auditor's note.
A Corporate Governance Statement has been published as part of the Annual Report 2020 at:
https://www.reveniogroup.fi/fi/sijoittajat/hallinnointi (in Finnish)
https://www.reveniogroup.fi/en/investors/corporate_governance (in English)
In addition, a separate Remuneration Report of 2020 has been published in Finnish and English at:
The Annual Report, Report by the Board of Directors and Financial Statements, Corporate Governance Statement as well as the Remuneration Report are all pdf-attachments to this Stock Exchange Release.
Revenio does not publish a printed Annual Report.
Revenio Group Corporation
Board of Directors
For further information, please contact:
CFO Robin Pulkkinen, tel. +358 50 505 9932
Nasdaq Helsinki Ltd
Financial Supervisory Authority
Revenio Group in brief
Revenio is an internationally operating health technology corporation and a globally leading supplier of ophthalmic devices. Revenio Group's eye diagnostics solutions include tonometers, retinal imaging apparatus and perimeters under the iCare brand. The main tool for the detection and diagnosis of glaucoma and its monitoring during treatment are intraocular pressure measurement (tonometry), retinal imaging, and visual field tests (perimetry).
The Revenio Group consists of Revenio Group Corporation, Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.
In 2020, Revenio Group's net sales totalled EUR 61.1 million, with its net operating profit standing at EUR 17.1 million. Revenio Group Corporation's shares are listed on Nasdaq Helsinki with the trading code REG1V.